These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 33859115)

  • 21. Emicizumab for hemophilia A with factor VIII inhibitors.
    Young G; Callaghan M; Dunn A; Kruse-Jarres R; Pipe S
    Expert Rev Hematol; 2018 Nov; 11(11):835-846. PubMed ID: 30278802
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Spinal epidural haematoma in haemophilia A with inhibitors--efficacy of recombinant factor VIIa concentrate.
    Leach M; Makris M; Hampton KK; Preston FE
    Haemophilia; 1999 May; 5(3):209-12. PubMed ID: 10444290
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Emicizumab Use in Treatment of Acquired Hemophilia A: A Case Report.
    Al-Banaa K; Alhillan A; Hawa F; Mahmood R; Zaki A; El Abdallah M; Zimmerman J; Musa F
    Am J Case Rep; 2019 Jul; 20():1046-1048. PubMed ID: 31318850
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Utilization of emicizumab in acquired hemophilia A: A case report.
    Yates SG; Webb CB; Sarode R; Ibrahim IF; Shen YP
    Transfus Apher Sci; 2022 Dec; 61(6):103457. PubMed ID: 35643753
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Emicizumab: a paradigm shift in hemophilia treatment].
    Nogami K
    Rinsho Ketsueki; 2020; 61(5):536-541. PubMed ID: 32507821
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Economic impact model of delayed inhibitor development in patients with hemophilia a receiving emicizumab for the prevention of bleeding events.
    Patel AM; Corman SL; Chaplin S; Raimundo K; Sidonio RF
    J Med Econ; 2019 Dec; 22(12):1328-1337. PubMed ID: 31530050
    [No Abstract]   [Full Text] [Related]  

  • 27. Emicizumab for hemophilia A without inhibitors.
    Cafuir L; Kruse-Jarres R; Mancuso ME; Kempton CL
    Expert Rev Hematol; 2019 Jul; 12(7):515-524. PubMed ID: 31130012
    [No Abstract]   [Full Text] [Related]  

  • 28. A comparison between on-demand usage of rFVIIa vs prophylaxis use of emicizumab in high titer inhibitory hemophilia A patients in Iran: A cost-utility analysis.
    Saiyarsarai P; Robabpour Derakhshan A; Khedmati J; Eshghi P; Seyedifar M
    Medicine (Baltimore); 2021 Oct; 100(40):e27303. PubMed ID: 34622828
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Emicizumab for routine prophylaxis to prevent bleeding episodes in patients with hemophilia A.
    Díaz-Ricart M; Isola IM; Escolar G
    Drugs Today (Barc); 2018 Oct; 54(10):591-600. PubMed ID: 30398480
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-world case series and summary of current literature of infants and toddlers with severe hemophilia A with inhibitor on prophylaxis with emicizumab.
    Garcia J; Zia A
    Pediatr Blood Cancer; 2021 May; 68(5):e28942. PubMed ID: 33559300
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Should emicizumab be used in patients with acquired hemophilia A?
    Tiede A; Kemkes-Matthes B; Knöbl P
    J Thromb Haemost; 2021 Mar; 19(3):637-644. PubMed ID: 33306259
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Port removal in patients receiving emicizumab prophylaxis: A single centre experience and review of the literature.
    Swan D; Paran S; Nolan B
    Haemophilia; 2022 Jan; 28(1):42-45. PubMed ID: 34786787
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bispecific Antibody Emicizumab for Haemophilia A: A Breakthrough for Patients with Inhibitors.
    Mahlangu JN
    BioDrugs; 2018 Dec; 32(6):561-570. PubMed ID: 30430367
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors.
    Mahlangu J; Oldenburg J; Paz-Priel I; Negrier C; Niggli M; Mancuso ME; Schmitt C; Jiménez-Yuste V; Kempton C; Dhalluin C; Callaghan MU; Bujan W; Shima M; Adamkewicz JI; Asikanius E; Levy GG; Kruse-Jarres R
    N Engl J Med; 2018 Aug; 379(9):811-822. PubMed ID: 30157389
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bridging the Missing Link with Emicizumab: A Bispecific Antibody for Treatment of Hemophilia A.
    Gelbenegger G; Schoergenhofer C; Knoebl P; Jilma B
    Thromb Haemost; 2020 Oct; 120(10):1357-1370. PubMed ID: 32717759
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Consecutive complex percutaneous coronary interventions using emicizumab and recombinant activated factor VII in a patient with severe haemophilia A and high-titre inhibitor.
    Chen YW; Chen WJ; Tseng MS; Lo HC; Shih MY; Chen YJ; Lee WL; Wang JD
    Haemophilia; 2021 May; 27(3):e385-e388. PubMed ID: 32997880
    [No Abstract]   [Full Text] [Related]  

  • 37. Prophylaxis for hemophilia A without inhibitors: treatment options and considerations.
    Valentino LA; Khair K
    Expert Rev Hematol; 2020 Jul; 13(7):731-743. PubMed ID: 32573295
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hemophilic pseudotumor of the maxillary sinus in an inhibitor-positive patient with hemophilia A receiving emicizumab: a case report.
    Kawahara F; Shirayama R; Ito T; Oshida K; Sato T; Kusuhara K
    Int J Hematol; 2022 Jun; 115(6):906-912. PubMed ID: 35079962
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Emicizumab for the prevention of bleeds in hemophilia A.
    Mahlangu J
    Expert Opin Biol Ther; 2019 Aug; 19(8):753-761. PubMed ID: 31150297
    [No Abstract]   [Full Text] [Related]  

  • 40. Use of thrombin generation assay to personalize treatment of breakthrough bleeds in a patient with hemophilia and inhibitors receiving prophylaxis with emicizumab.
    Dargaud Y; Lienhart A; Janbain M; Le Quellec S; Enjolras N; Negrier C
    Haematologica; 2018 Apr; 103(4):e181-e183. PubMed ID: 29472355
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.